TY - JOUR
T1 - Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages
T2 - The PSERENADE project
AU - The PSERENADE Team
AU - Yang, Yangyupei
AU - Knoll, Maria Deloria
AU - Herbert, Carly
AU - Bennett, Julia C.
AU - Feikin, Daniel R.
AU - Garcia Quesada, Maria
AU - Hetrich, Marissa K.
AU - Zeger, Scott L.
AU - Kagucia, Eunice W.
AU - Xiao, Melody
AU - Cohen, Adam L.
AU - van der Linden, Mark
AU - du Plessis, Mignon
AU - Yildirim, Inci
AU - Winje, Brita A.
AU - Varon, Emmanuelle
AU - Valenzuela, Maria Teresa
AU - Valentiner-Branth, Palle
AU - Steens, Anneke
AU - Scott, J. Anthony
AU - Savrasova, Larisa
AU - Sanz, Juan Carlos
AU - Khan, Aalisha Sahu
AU - Oishi, Kazunori
AU - Nzoyikorera, Néhémie
AU - Nuorti, J. Pekka
AU - Mereckiene, Jolita
AU - McMahon, Kimberley
AU - McGeer, Allison
AU - Mackenzie, Grant A.
AU - MacDonald, Laura
AU - Ladhani, Shamez N.
AU - Kristinsson, Karl G.
AU - Kleynhans, Jackie
AU - Kellner, James D.
AU - Jayasinghe, Sanjay
AU - Ho, Pak Leung
AU - Hilty, Markus
AU - Hammitt, Laura L.
AU - Guevara, Marcela
AU - Gilkison, Charlotte
AU - Gierke, Ryan
AU - Desmet, Stefanie
AU - De Wals, Philippe
AU - Dagan, Ron
AU - Colzani, Edoardo
AU - Ciruela, Pilar
AU - Chuluunbat, Urtnasan
AU - Chan, Guanhao
AU - Camilli, Romina
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025/3
Y1 - 2025/3
N2 - Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally. Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5–17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types. Results: Analyses included 10,168 cases <5 y from PCV13 sites and 2849 from PCV10 sites, 3711 and 1549 for 5–17 y and 29,187 and 5653 for ≥18 y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 48–74% across products and PCV7 impact strata for children <5 y, 35–62% for 5–17 y and 0–36% for ≥18 y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5 y: 96–100%; 5–17 y: 77–85%; ≥18 y: 73–85%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups. Conclusion: Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited.
AB - Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally. Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5–17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types. Results: Analyses included 10,168 cases <5 y from PCV13 sites and 2849 from PCV10 sites, 3711 and 1549 for 5–17 y and 29,187 and 5653 for ≥18 y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 48–74% across products and PCV7 impact strata for children <5 y, 35–62% for 5–17 y and 0–36% for ≥18 y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5 y: 96–100%; 5–17 y: 77–85%; ≥18 y: 73–85%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups. Conclusion: Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited.
KW - Incidence
KW - Indirect protection
KW - Pneumococcal conjugate vaccines
KW - Pneumococcal meningitis
KW - Serotype replacement
KW - Serotypes
KW - Vaccine impact
UR - http://www.scopus.com/inward/record.url?scp=85217119857&partnerID=8YFLogxK
U2 - 10.1016/j.jinf.2025.106426
DO - 10.1016/j.jinf.2025.106426
M3 - Article
C2 - 39864526
AN - SCOPUS:85217119857
SN - 0163-4453
VL - 90
JO - Journal of Infection
JF - Journal of Infection
IS - 3
M1 - 106426
ER -